In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 39-47

  Snoek, Robert ^a   Cheng, Helen ^a   Margiotti, Katia ^a   Wafa, Latif A ^a   Wong, Charmaine A ^a   Wong, Erica Chan ^a   Fazli, Ladan ^a   Nelson, Colleen C ^a   Gleave, Martin E ^a   Rennie, Paul S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BLASTICIDIN S; DOXYCYCLINE HYCLATE; LUCIFERASE; MESSENGER RNA; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN; PUROMYCIN; SHORT HAIRPIN RNA;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CASTRATION; CELL CYCLE REGULATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVATION; EXPERIMENTAL MOUSE; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REPORTER GENE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; CASTRATION; CELL LINE, TUMOR; GENE TARGETING; HUMANS; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 58949101975     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1726     Document Type: Article

References (43)

1. Jemal A, Siegel R.Ward E, MurrayT, Xu J.Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
2. Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis1998;1:289-96.
3. Albertsen PC, HanleyJA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005:293:2095-101.
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004:351: 1502-12.
5. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004:91:483-90.
6. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res1994;54:4096-102.
7. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995:55:3068-72.
8. Chen CD, Welsbie DS.Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
9. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997:57:314-9.
10. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003:21:2673-8.
11. Ma AH, Xia L, Desai SJ, et al. Male germ cell associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells. Cancer Res 2006:66:8439 - 47.
12. Zheng Z, Cai C, Omwancha J, Chen SY BaslanT, Shemshedini L. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation- independent mechanism in prostate cancer cells. J Biol Chem 2006:281:4002-12.
13. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002:23: 175-200.
14. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer: Part 2. Androgen-receptor cofactors and bypass pathways. BJU Int 2005;95:1327-35.
15. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer: Part 1. Modifications to the androgen receptor. BJU Int 2005:95:1320-6
16. Hendriksen PJ, Dits NF, Kokame K, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006:66:5012-20.
17. Tomlins SA, Rhodes DR. Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005:310:644 8
18. Wang J, Cai Y. Ren C. Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer Cancer Res 2006:66:8347-51.
19. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer Endocr Relat Cancer 2004:11:459 - 76
20. Cheng H. Snoek R. Ghaidi F. Cox ME, Rennie PS Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression Cancer Res 2006:66 10613-20.
21. Kojima S. Mulholland DJ, Ettinger S. Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models Prostate 2006:66 971 -86.
22. Margiotti K. Wafa LA. Cheng H. Novelli G, Nelson CC, Rennie PS. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells Mol Cancer 2007:6:38
23. Wafa LA, Palmer J, Fazli L, et al. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleaon grade prostate tumors. Hum Pathol 2007;38:161 -70.
24. NgTL, Gown AM, BarryTS, etal. Nuclear β-catenin in mesenchymal tumors. Mod Pathol 2005;18:68-74.
25. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer1994;57:406-12.
26. Zegarra-Moro OL, Schmidt LJ, Huang H.Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
27. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005;96:251-8.
28. Yuan X, Li T, Wang H, et al. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 2006;169:682-96.
29. Liao X.Tang S,Thrasher JB, GrieblingTL, Li B. Small interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol CancerTher 2005;4:505-15.
30. Chen L, Meng S.Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005;4:1311-9.
31. Bhuiyan MM, LiY, Banerjee S, etal. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006;66:10064-72.
32. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93
33. Zimmermann KC, Green DR. How cells die: apoptosis pathways. J Allergy Clin Immunol 2001;108:S99-103.
34. OmezzineA, Mauduit CJabone E, Nabli N, Bouslama A, Benahmed M. Caspase-3 and -6 expression and activation are targeted by hormone action in the rat ventral prostate during the apoptotic cell death process. Biol Reprod 2003;69:752-60.
35. Massie CE, Adryan B, Barbosa-Morais NL, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 2007:8:871 -8.
36. XiaoW, Zhang Q, Jiang F, Pins M, Kozlowski JM.Wang Z. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 2003;63:4698-704.
37. Morrison BH, Bauer JA, Hu J, et al. Inositol hexaki sphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. Oncogene 2002;21:1882-9.
38. Cuddeback SM.Yamaguchi H, Komatsu K, et al. Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-containing protein that associates with Bax. J Biol Chem 2001;276: 20559-65.
39. Bartkova J. Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
40. Yarwood S, Bouyoucef-Cherchalli D, Cullen PJ, Kupzig S. The GAP1 family of GTPase-activating proteins: spatial and temporal regulators of small GTPase signalling, Biochem Soc Trans 2006;34:846-50.
41. Gioeli D. Signal transduction in prostate cancer progression. Clin Sci (Lond) 2005;108:293-308.
42. Shi Y, Vattem KM, Sood R, et al. Identification and characterization of pancreatic eukaryotic initiation factor 2 α-subunit kinase, PEK, involved in translational control. Mol Cell Biol 1998;187499-509.
43. Wright ME.Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17:1726-37.